Paul D. Savage

Paul D. Savage

Auto-generated profile, based on publicly available information

Paul D. Savage

Wake Forest Baptist Medical Center, Winston-Salem, NC

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Sarcoma
Verified
Journal Article
Open access
PDF file
PSPaul D. Savage
Paul D. Savage
JLJames Lovato
James Lovato
KBK. Bridget Brosnihan
K. Bridget Brosnihan
AMAntonius A. Miller
Antonius A. Miller
WPW. Jeffrey Petty
W. Jeffrey Petty
Background. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous antiangiogenic hormone with anticancer activity. In a phase I study of Ang-(1-7), two of three patients with metastatic sarcoma experienced disease stabilization. This phase II study examined clinical and biomarker outcomes for patients with metastatic sarcoma. Methods. Ang-(1-7) was administered by subcutaneous injection at a dose of 20 mg daily. If excessive toxicities occurred in the first cohort, a dose deescalation cohort was allowed. Blood samples were obtained to measure changes in biomarkers. Results. Treatment was well-tolerated and the dose deescalation cohort was not required. Plasma PlGF concentrations following treatment were not statistically significantly changed. A significant increase in plasma Ang-(1-7) was observed at 4 hours after injection. The median progression-free survival was 2.7 months (95% CI; 1.4 to 4.1 months), and the median overall survival was 10.2 months (95% CI; 5.3 to 18.3 months). Two patients with vascular sarcomas demonstrated prolonged disease stabilization of 10 months (hemangiopericytoma) and 19 months (epithelioid hemangioendothelioma). Conclusions. Ang-(1-7) at a dose of 20 mg daily was well-tolerated. This prospective phase II study failed to confirm the PlGF biomarker effect identified in the prior phase I study. Prolonged disease stabilization in hemangiopericytoma and epithelioid hemangioendothelioma may warrant further investigation.

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
AHA. Henson
A. Henson
EME. McTyre
E. McTyre
DADiandra Norelle Ayala-Peacock
Diandra Norelle Ayala-Peacock
PTP. Triozzi
P. Triozzi
PSP. Savage
P. Savage
MCMichael Chan
Michael Chan